Try our mobile app

General information

Country: UNITED STATES

Sector: Oil and Gas E and P

PermRock Royalty Trust engages in the acquisition, development, and operation of oil and natural gas properties in the Permian Basin. The company is headquartered in Fort Worth, Texas. The firm is focused on the acquisition, development and operation of oil and natural gas properties in the Permian Basin. The Company’s underlying properties are located in the Permian Basin, which extends over 75,000 square miles in West Texas and Southeastern New Mexico. The Company’s property consists of multiple stacked hydrocarbon-bearing formations. As of April 6, 2018 it has produced approximately 30 billion barrels (Bbls) of oil and 75 trillion cubic feet (Tcf) of natural gas.
  • Dividend yield for the last twelve months 11.7%
  • Free cash flow yield 0.0% (LTM)
  • Share price is 10.4% higher than minimum and 66.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (4.9x vs
    )

Key Financials (Download financials)

Ticker: PRT
Share price, USD:  (-0.5%)3.62
year average price 4.06  


year start price 4.57 2023-12-28

max close price 4.74 2024-01-29

min close price 3.28 2024-12-18

current price 3.62 2024-12-26
Common stocks: 12 165 700

Dividend Yield:  11.7%
EV / LTM EBITDA: 4.9x
EV / EBITDA annualized: 3.7x
Target EV / EBITDA (hist percentile):
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 44
Net Debt ($m): 0
EV (Enterprise Value): 44
EBITDA LTM ($m): 9
EV / LTM EBITDA: 4.9x
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / LTM EBITDA and 75% percentile

Potential dynamics

News


2024-12-20prnewswire.com

PermRock Royalty Trust Declares Monthly Cash Distribution

2024-12-11globenewswire.com

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

2024-11-18prnewswire.com

PermRock Royalty Trust Declares Monthly Cash Distribution

2024-10-21prnewswire.com

PermRock Royalty Trust Declares Monthly Cash Distribution

2024-09-20prnewswire.com

PermRock Royalty Trust Declares Monthly Cash Distribution

2024-09-13globenewswire.com

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

2024-08-20prnewswire.com

PermRock Royalty Trust Declares Monthly Cash Distribution

2024-07-19prnewswire.com

PermRock Royalty Trust Declares Monthly Cash Distribution

2024-06-17prnewswire.com

PermRock Royalty Trust Declares Monthly Cash Distribution

2024-05-20prnewswire.com

PermRock Royalty Trust Declares Monthly Cash Distribution
More information for subscribed users:
detailed calculation of Potential,
commodities and currency affecting the company